tbuckley/cabot-search huggingface dataset:
PD1/PD-L1 inhibition as a potential radiosensitizer in head and neck squamous cell carcinoma: a case report
Authors: Misako Nagasaka, Mark Zaki, Harold Kim, S. Naweed Raza, George Yoo, Ho-sheng Lin, Ammar Sukari
Journal: Journal for ImmunoTherapy of Cancer (2016)

Immunotherapy targeting the checkpoint PD1 (programmed cell death protein 1) or PDL1 (programmed death ligand 1) has led to advances in the treatment of melanoma and non-small cell lung cancer (NSCLC). The use of such therapies has also been introduced into the treatment of other malignancies, including head and neck cancer. The combined effects of checkpoint inhibitors and anti-PD1(L1) antibodies and radiation therapy have not yet been sufficiently investigated.
Symptom Burden Profile in Myelofibrosis Patients with Thrombocytopenia: Lessons and Unmet Needs
Authors: Holly Geyer, Robyn M Scherber, Heidi Kosiorek, Amylou C. Dueck, Jean-Jacques Kiladjian, Zhijian Xiao, Stefanie Slot, Sonja Zweegman, Federico Sackmann, Ana Kerguelen Fuentes, Dolores Hernandez-Maraver, Konstanze Dohner, Claire N. Harrison, Deepti Radia, Pablo J. Muxi, Carlos Besses, Francisco Cervantes, Peter L. Johansson, Bjorn Andreasson, Alessandro Rambaldi, Tiziano Barbui, Karin Bonatz, Andreas Reiter, Francoise Boyer, Gabriel Etienne, Jean-Christophe Ianotto, Dana Ranta, Lydia Roy, Jean-Yves Cahn, Norman I Maldonado, Giovanni Barosi, Maria Ferrari, Robert Peter Gale, Gunnar Birgegard, Zefeng Xu, Yue Zhang, Xiujuan Sun, Junqing Xu, Peihong Zhang, Peter te Boekhorst, Suzan Commandeur, Harry C. Schouten, Heike L Pahl, Martin Griesshammer, Frank Stegelmann, Thomas Lehmann, Alessandro M. Vannucchi, Francesco Passamonti, Jan Samuelsson, Ruben A. Mesa
Journal: Blood (2015)
Incidence of Intensive Care Unit Admission, Outcome, and Post Intensive Care Survival in Patients with Acute Lymphocytic Leukemia or Burkitt Lymphoma
Authors: Peter Schellongowski, Philipp Wohlfarth, Kundi Michael, Alexander Hauswirth, Andja Bojic, Werner Rabitsch, Ulrich Jäger, Peter Valent, Thomas Staudinger, Wolfgang R. Sperr
Journal: Blood (2014)
Gene Expression Profiling (GEP) of CD138-Purified Plasma Cells: Modeling for High LDH and Cytogenetic Abnormalities as Independently Adverse Features of Multiple Myeloma (MM) In Total Therapy (TT) Protocols
Authors: Pingping Qu, Jeff Haessler, John Shaughnessy, John Crowley, Bart Barlogie
Journal: Blood (2010)
PTU-135 How Much Gluten is the General Population Consuming and Does It Relate to Symptoms?
Authors: M Kurien, I Aziz, N Trott, DO Brien, HA George, MY Hossain, LJS Marks, JI Richardson, R Rigby, DS Sanders
Journal: Gut (2016)

<h3>Introduction</h3> Gluten is a ubiquitous part of a western diet. It is implicated for causing an array of disorders, which have both intestinal and/or extraintestinal manifestations. Our understanding of this heterogeneous group of gluten-related disorders is advancing, however uncertainty exists as to how much gluten the general population is consuming. This study aims to address this knowledge gap and also assess the prevalence of self-reported gluten sensitivity within the general population. <h3>Methods</h3> Between September and October 2015 a population-based survey was undertaken in Sheffield, UK. Members of the general public, all over the age of 16 years, were invited to complete a modified version of a previously validated written questionnaire. This questionnaire assessed demographic information, GI conditions and also determined the presence of gluten sensitivity (GS). In addition, total gluten consumption was calculated using a food frequency questionnaire. Participants were asked about their use of a gluten free diet (GFD), and whether they had seen a healthcare professional for their symptoms. A diagnosis of coeliac disease (CD) was determined if individuals had a doctor diagnosis of CD, and were also taking a GFD. <h3>Results</h3> 1003 adults completed the population-based survey (59% female, median age 31 years (16–86 years). The mean consumption of gluten per day for this group was 13.2 g (s.d =9.2 g). The self-reported prevalence of GS was 32.5% (326/1003, female 70% [P &lt; 0.0001], age range 17–82, median age 35 yrs), with 3.7% (38/1003) on a GFD and 1.1% (12/1003) having CD. The proportion of GS individuals who had seen a doctor for their symptoms was 18.3% (65/326). Individuals with GS had an increased prevalence of fulfilling the Rome III criteria for irritable bowel syndrome, in comparison with those without GS (31.3% vs. 5.61%, odds ratio 7.66, p &lt; 0.0001). In addition, mean daily consumption of gluten was considerably lower in this GS group compared to the non GS group (10.8 g vs. 14.4 g, p &lt; 0.0001). <h3>Conclusion</h3> This is the first study assessing gluten consumption in a UK population. Findings from our work highlight that sensitivity to gluten-based products is common, and that affected individuals have a higher prevalence of IBS. Although only a minority of individuals maintained a gluten-free diet, individuals with gluten related symptoms evidently were electing to reduce their gluten consumption. <h3>Disclosure of Interest</h3> None Declared
The Prognostic Role of Androgen Receptor in Patients with Early-Stage Breast Cancer: A Meta-analysis of Clinical and Gene Expression Data
Authors: Ivana Bozovic-Spasojevic, Dimitrios Zardavas, Sylvain Brohée, Lieveke Ameye, Debora Fumagalli, Felipe Ades, Evandro de Azambuja, Yacine Bareche, Martine Piccart, Marianne Paesmans, Christos Sotiriou
Journal: Clinical Cancer Research (2016)

Abstract Purpose: Androgen receptor (AR) expression has been observed in about 70% of patients with breast cancer, but its prognostic role remains uncertain. Experimental Design: To assess the prognostic role of AR expression in early-stage breast cancer, we performed a meta-analysis of studies that evaluated the impact of AR at the protein and gene expression level on disease-free survival (DFS) and/or overall survival (OS). Eligible studies were identified by systematic review of electronic databases using the MeSH-terms “breast neoplasm” and “androgen receptor” and were selected after a qualitative assessment based on the REMARK criteria. A pooled gene expression analysis of 35 publicly available microarray data sets was also performed from patients with early-stage breast cancer with available gene expression and clinical outcome data. Results: Twenty-two of 33 eligible studies for the clinical meta-analysis, including 10,004 patients, were considered as evaluable for the current study after the qualitative assessment. AR positivity defined by IHC was associated with improved DFS in all patients with breast cancer [multivariate (M) analysis, HR 0.46; 95% confidence interval (CI) 0.37–0.58, P &amp;lt; 0.001] and better OS [M-HR 0.53; 95% CI, 0.38–0.73, P &amp;lt; 0.001]. Thirty-five datasets including 7,220 patients were eligible for the pooled gene expression analysis. High AR mRNA levels were found to confer positive prognosis overall in terms of DFS (HR 0.82; 95% CI 0.72–0.92;P = 0.0007) and OS (HR 0.84; 95% CI, 0.75–0.94; P = 0.02) only in univariate analysis. Conclusions: Our analysis, conducted among more than 17,000 women with early-stage breast cancer included in clinical and gene expression analysis, demonstrates that AR positivity is associated with favorable clinical outcome. Clin Cancer Res; 23(11); 2702–12. ©2016 AACR.
THU0511 Factors Associated with Preclinical Atherosclerotic Changes in Carotid Artery in Men with Gout
Authors: H. Tag, G. Kim, E. Park, D. Koo, J. Lee, S. Kim
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Although a number of studies have reported that hyperuricemia and gout are independent risk factors for the development of cardiovascular disease (CVD), little is known about the relationship between hyperuricemia or gout and arterial stiffness. <h3>Objectives</h3> This study sought to compare carotid arterial stiffness in gout patients and healthy controls, and evaluate the predictive factors for arterial stiffness in male patients with gout using carotid ultrasonography. <h3>Methods</h3> In this cross-sectional study, 69 male gout patients and 64 male healthy controls without any known CVD were prospectively analyzed. Carotid artery stiffness index β (β-index) and the intima-media thickness (IMT) were measured as surrogate markers of preclinical atherosclerosis. We also measured serum uric acid, high sensitivity C-reactive protein (hsCRP), erythrocyte sedimentation rate (ESR), lipid profiles, and renal function. Adjusted comparison of the β-index and cIMT in both groups and their associations with clinical parameters were investigated. <h3>Results</h3> The gout group showed higher ESR, Cr, prevalence of HT and DM than the control group (p&lt;0.05). However, HDL was higher in the control group (p&lt;0.05). β-index and cIMT were higher in the gout group, but only β-index showed a statistically significant difference (11.12 ± 5.19 vs 8.68 ± 3.67, p=0.002). Multiple regression analyses showed that duration of gout was significantly associated with increased β-index and cIMT in the gout group (Table 1). <h3>Conclusions</h3> Patients with gout had increased carotid arterial stiffness, which was significantly related to gout duration rather than serum uric acid level or status of inflammation. <h3>References</h3> Richette P, Perez-Ruiz F, Doherty M, Jansen TL, Nuki G, Pascual E, Punzi L, So AK, Bardin T. (2014) Improving cardiovascular and renal outcomes in gout: what should we target? Nat Rev Rheumatol. 10(11):654–61. Perez-Ruiz F, Becker MA. (2015) Inflammation: a possible mechanism for a causative role of hyperuricemia/gout in cardiovascular disease. Curr Med Res Opin. 31 Suppl 2:9–14. <h3>Disclosure of Interest</h3> None declared
PTH-146 Oesophageal Variceal Surveillance - Should Community Hospital Endoscopy Units in Gloucestershire Jump On The ‘Band-Wagon’?
Authors: LB Materacki, C Hollywood, D Beech
Journal: Gut (2016)

<h3>Introduction</h3> Patients with liver cirrhosis should engage with a variceal surveillance programme to minimise the risk of variceal bleeding, a major cause of morbidity and mortality.<sup>1</sup> To improve compliance with variceal surveillance it is important to adopt a patient-centred approach and optimise access to endoscopy. Although routine diagnostic upper endoscopy is already established in community hospitals in Gloucestershire safety fears obstruct the provision of variceal surveillance causing potentially unjustified inconvenience to patients. <h3>Methods</h3> This double-centre, observational study investigated the safety of endoscopic variceal surveillance in adult cirrhotic patients (age range: 29–90 y) and evaluated the feasibility for service expansion into community hospital endoscopy units. Information was collected retrospectively from an electronic database of patients who underwent elective endoscopic variceal surveillance in Gloucester Royal Hospital or Cheltenham General Hospital from February 2013 to August 2014. The medical notes of patients who underwent variceal banding were evaluated for short-term complications of band ligation and length of hospital stay. <h3>Results</h3> 223 patients underwent endoscopy for variceal surveillance during the 18 month study period. Of these patients 12.1% (n = 27) required endoscopic band ligation including 7 patients with history of variceal haemorrhage. All patients underwent endoscopy as a day-case procedure with same-day discharge regardless of the need for band ligation. Variceal band ligation was not associated with any significant complications within 7 days. <h3>Conclusion</h3> Endoscopy for variceal surveillance is a safe day-case procedure irrespective of the need for band ligation. The safety concerns obstructing the use of existing endoscopy resources for variceal surveillance in community hospitals in Gloucestershire are unjustified. Broadening access to variceal surveillance represents a cost-effective means to make care more patient-centred. This may improve compliance with variceal surveillance and reduce variceal bleeding in cirrhotics. <h3>Reference</h3> 1 Tripathi D, <i>et al</i>. UK guidelines on the management of variceal haemorrhage in cirrhotic patients. <i>Gut</i> 2015;<b>64</b>(11):1680-1704 doi:10.1136/gutjnl-2015-309262 <h3>Disclosure of Interest</h3> None Declared
Phase 1 Clinical Investigation of Human Myeloid Progenitor Cells (CLT-008) As a Supportive Care Measure during Chemotherapy for Acute Myeloid Leukemia (AML)
Authors: Matthew J. Wieduwilt, Jan Cerny, Luke Akard, Celalettin Ustun, Farhad Ravandi, James M. Rossetti, Brian T. Hill, Janice (Wes) Brown, Lois Kellerman, Rod Van Syoc, William Reed, Charalambos Andreadis
Journal: Blood (2014)
Anti-β2-GPI Antibodies Induce Von Willebrand Factor Release, Modulate Platelet Binding, and Affect VWF Proteolysis
Authors: Christopher J. Ng, Keith R. McCrae, Junmei Chen, Michael Wang, Marilyn J. Manco-Johnson, Dominic W Chung, Tara C White-Adams, Jose A Lopez, Jorge A Di Paola
Journal: Blood (2014)
CD109 Deficiency Induces Preferential Proliferation of the Piga Mutant Leukemia Cell Line TF-1 in the Presence of TGF-β
Authors: Kohei Hosokawa, Takamasa Katagiri, Chizuru Saito, Luis J. Espinoza, Yumi Sasaki, Yu Seiki, Yasuhiko Yamamoto, Hirohito Yamazaki, Shinji Nakao
Journal: Blood (2012)
Distinct Relationships Between Visual and Auditory Perceptual Abnormalities and Conversion to Psychosis in a Clinical High-Risk Population
Authors: Eugénie Lehembre-Shiah, Wei Leong, Gary Brucato, Anissa Abi-Dargham, Jeffrey A. Lieberman, Guillermo Horga, Ragy R. Girgis
Journal: JAMA Psychiatry (2016)
Oral, ultra–long-lasting drug delivery: Application toward malaria elimination goals
Authors: Andrew M. Bellinger, Mousa Jafari, Tyler M. Grant, Shiyi Zhang, Hannah C. Slater, Edward A. Wenger, Stacy Mo, Young-Ah Lucy Lee, Hormoz Mazdiyasni, Lawrence Kogan, Ross Barman, Cody Cleveland, Lucas Booth, Taylor Bensel, Daniel Minahan, Haley M. Hurowitz, Tammy Tai, Johanna Daily, Boris Nikolic, Lowell Wood, Philip A. Eckhoff, Robert Langer, Giovanni Traverso
Journal: Science Translational Medicine (2016)

A newly developed platform capable of oral, ultra–long-acting drug delivery could be applied against the malaria vector in elimination programs.
SAT0501 HLA System in Chlamyidia Trachomatis-Induced Reactive Arthritis
Authors: V. Dostanko, N. Dostanko, V. Yagur, K. Chizh
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> It should be noted considerable incidence rate of reactive arthritis (ReA) in the last decades and the fact that the majority of them are due to Chlamydia trachomatis infection (CTI) [1,2]. In some patients with CTI ReA and chronic ReA will develop [3,4], therefore search for risk factors of possible ReA development in CTI patients is an essential problem. <h3>Objectives</h3> To perform the typing of ReA patients induced by CTI for HLA antigens in order to reveal possible genetic markers of susceptibility and resistance to ReA development. <h3>Methods</h3> 30 ReA patients observed in Byelorussian Republican Rheumatologic Center (17 women and 13 men from 19 to 56 years old, mean age 36.4±10.5 years) with urogenital CTI confirmed by culture and immunofluorescence serology were studied for frequency of I and II class HLA antigens (A, B, C, DR, DQ locus, total number of studied specificities - 71) by means of microdroplet lymphocyte cytotoxicity test. Data on frequency of I and II class HLA antigens in 308 and 106 unrelated Minsk (Belarus) inhabitants were used as a control. <h3>Results</h3> We revealed significant increase of antigen frequency in B locus for B27 (χ<sup>2</sup>=26.5; p<sub>corr</sub>=0.00025; RR=5.7) and B60 (χ<sup>2</sup>=4.3; p&lt;0.05; RR=2.7) antigens, in DR locus for DR1 (43.3% in ReA vs 16.6% in controls, χ<sup>2</sup>=10.1; RR=4.0) and DR13 (40.0% in ReA vs 21.7% in controls, χ<sup>2</sup>=4.1; RR=2.4) antigens as well as for phenotype DR1,DR13 frequency (χ<sup>2</sup>=5.3; p&lt;0.05, RR=5.3) in ReA patients. In addition significant decrease of DR7 (10.0% vs 32.1% in controls, χ<sup>2</sup>=5.8; RR=-4.2), DR11 (13.3% vs 31.1%, χ<sup>2</sup>=3.7; RR=-2.9) and DR53 (23.3% vs 47.2% χ<sup>2</sup>=5.4; RR=-2.9) antigen frequency was revealed in ReA patients. We registered significant increase of antigen DQ5 frequency (56.7% vs 28.3%, χ<sup>2</sup>=8.3; RR=3.3) as well as phenotype DQ5,6 frequency (χ<sup>2</sup>=10.1; RR=16.2) and significant decrease of antigen DQ2 frequency (20.0% vs 37.7%, χ<sup>2</sup>=3.4; RR=-2.4) in ReA patients in comparison with controls. <h3>Conclusions</h3> The revealed genetic markers of susceptibility to ReA development in patients with urogenital CTI are: HLA B27, B60, DR1, DR13, DQ5 antigens, as well as DR1, DR13 and DQ5, DQ6 phenotypes. We consider DR7, DR11, DR53, DQ2 antigens as factors of resistance to ReA development. <h3>References</h3> Soderlin M.K. et al. Annual incidence of inflammatory joint disease in a population based study in southern Sweden // Ann. Rheum. Dis. 2002; 61:911–915. Whittum-Hudson J.A., Hudson A.P. Human chlamydial infections: persistence, prevalence, and prospects for the future // Nat. Sci. Soc. 2005; 13:371–382. Rizzo A. et al. Role of Chlamydia and Chlamydophila infections in reactive arthritis // Int. Med. 2012; 51:113–117. Carter J.D. et al. Chlamydia and chronic arthritis//Ann Med. 2012 Dec; 44(8):784–92. <h3>Disclosure of Interest</h3> None declared
Activity of the Investigational Antibody–Drug Conjugate Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large-Cell Lymphoma: Comparisons with Meta-Analyses of Historical Control Chemotherapy Data
Authors: Antonio Gualberto, Andy Chi, Yi Liu
Journal: Blood (2011)
Therapy for Cellulitis
Authors: Adam B. Raff, Daniela Kroshinsky
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
OC-073 The First Multicentre Experience from The UK and Ireland of the Use of the Hot Axios System for Transluminal Drainage of Pancreatic Fluid Collections
Authors: SV Venkatachalapathy, A Makin, SP Pereira, GJ Johnson, N Bekkali, I Penman, KW Oppong, MK Nayar, NR Carroll, EM Godfrey, BM Ryan, V Parihar, CJ McKay, MT Huggett
Journal: Gut (2016)

<h3>Introduction</h3> Pancreatic fluid collections (PFC) are a common local complication of pancreatitis with incidences of 5–16% and 20–40% in acute and chronic pancreatitis, respectively.<sup>1</sup> Classification of PFC includes acute peripancreatic fluid collection, pancreatic pseudocyst, acute necrotic collection and walled-off necrosis (WON). A new lumen-apposing, covered self-expanding metal stent on a catheter-based delivery system (Hot AXIOS, Boston Scientific) may have higher technical success rates, easier deployment and lower migration than plastic stents. We present the first multicentre prospective case series from the UK and Ireland to assess success and complication rates associated with Hot AXIOS stent for the drainage of PFC. <h3>Methods</h3> All adult patients who had Hot AXIOS stent placement for PFC from July 2015-February 2016 were included. Eight centres participated (London, Glasgow, Edinburgh, Newcastle, Cambridge, Manchester, Dublin and Leeds). All patients had CT of the PFC prior to placement. Data including technical success, resolution of collection, complications and stent migration were collected. <h3>Results</h3> Forty patients were treated with a single Hot AXIOS stent in each case. The median age was 57 years (range 31–78). 25 were male and 15 female. Indications were WON (24), pseudocyst (15) and abscess.<sup>1</sup> The median size of the PFC was 11 cm (4–20 cm). Thirty-eight patients (95%) had trans-gastric stents, 1 had trans-duodenal and 1 had a trans-oesophageal stent. Procedures were technically successful in all patients. Of 22 patients with available follow-up data to date, the collection resolved in 19 (86%) and reduced in size in 3 (14%). The median time to resolution was 36 (7–208) days. Twelve patients (30%) had 33 necrosectomies and/or endoscopic lavage following stent insertion. Stents migrated out in 2 patients and was displaced during necrosectomy in 1. Serious adverse events occurred in 1/40 (2.5%): a small bowel obstruction resulting from stent migration, managed surgically. There was no procedure related or 30 day mortality (data available in 27 patients). <h3>Conclusion</h3> This multicentre case series demonstrates that the Hot AXIOS system is safe and effective in draining PFC with a technical success rate of 100% and low serious adverse event rate. <h3>Reference</h3> 1 Banks PA, Bollen TL, Dervenis C, <i>et al</i>. Classification of acute pancreatitis—2012: Revision of the Atlanta classification and definitions by international consensus. <i>Gut</i> 2013. <h3>Disclosure of Interest</h3> None Declared